TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06427980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal formula HuoXue LiShui
Description: The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herbal formula Placebo
Description: The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
Study: NCT06584942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Subjects will titrate up to 20 mg of suvorexant daily. Subjects will follow a titration schedule with 10 mg once daily on days 1-3, 15 mg once daily on days 4-6, then 20 mg on day seven and for the remainder of the study. If participants report AEs (worsening depression/suicidal ideation, complex sleep behaviors, sleep paralysis, etc.) dose may be decreased to the previous dose taken. Participants will be treated for 14 days in total; however, due to scanner availability, the second scan may occur more than 14 days after the first scan. In this case, participants will be allowed to continue taking this dose for up to 14 additional days until the final scan occurs (28 days total).
Study: NCT06540339

Intervention type: OTHER
Intervention: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Description: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.

Intervention type: OTHER
Intervention: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Description: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.

Intervention type: OTHER
Intervention: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Description: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Study: NCT05398809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
Study: NCT05442593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Participants will perform: 8 sets of 10 maximal countermovement jumps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Participants will perform: 8 sets of 10 maximal countermovement jumps
Study: NCT06329544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Study: NCT06042270

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: 3 grams per day for \~4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 grams per day for \~4 weeks
Study: NCT06600815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preemptive stepwise infiltration anaesthesia(PSIA)
Description: For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative local infiltration analgesia(PLIA)
Description: Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
Study: NCT06324188

Intervention type: OTHER
Group type: OTHER
Intervention: Early atrial fibrillation ablation
Description: Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
Study: NCT06611657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antirotinib hydrochloride
Description: Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
Study: NCT06274892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring PROs
Description: Attendance at RT review appointments triaged based on remotely monitored PROs
Study: NCT06687616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynerGI
Description: Standardized 8-week CBT program, used for 20-30 minutes per week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: Distraction-based VR program with 2D nature videos to be used for 8 weeks, 2-2 times a week for 10 minutes
Study: NCT06384742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shift Worker Intervention for Sleep Health
Description: SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across seven approximately weekly sessions that range in length from 30-60 minutes
Study: NCT06072833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Financial Education / Navigation
Description: The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
Study: NCT06719596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Capsule
Description: enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
Study: NCT06721052

Intervention type: DRUG
Intervention: meta-Peng block
Description: The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.

Intervention type: DRUG
Intervention: Postoperative analgesia management
Description: We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
Study: NCT05152706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Cycling at the aerobic intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Cycling at the aerobic intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photons therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photons therapy
Study: NCT05294328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: LNZ101-combination ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine ophthalmic solution
Description: LNZ100- aceclidine ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Proprietary Ophthalmic Solution
Description: Proprietary Vehicle Ophthalmic Solution
Study: NCT05488002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Description: Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
Study: NCT04936035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection
Study: NCT06482996

Intervention type: OTHER
Intervention: Intraocular pressure (IOP) was measured
Description: The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.

Intervention type: OTHER
Intervention: Intraocular pressure (IOP) was measured
Description: The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
Study: NCT06331884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK1967 (Procizumab)
Description: DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK1967 (Procizumab)
Description: DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK1967 (Procizumab)
Description: DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo
Study: NCT05894824

Intervention type: DRUG
Group type: OTHER
Intervention: T-Dxd(Trastuzmab deruxtecan), Ramucirumab
Description: Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle
Study: NCT05462626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program
Description: The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
Study: NCT04665037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV 6 mg/kg
Description: POS 6 mg/kg body weight by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV 6 mg/kg
Description: POS 6 mg/kg body weight by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole PFS 6 mg/kg
Description: POS nominal 6 mg/kg body weight based on weight bands taken orally
Study: NCT05178316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP150
Description: Oral administration of JZP150 once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP150
Description: Oral administration of JZP150 once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo once daily in the morning
Study: NCT04848870

Intervention type: OTHER
Intervention: Salivary samples
Description: collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
Study: NCT06048783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program of systematic and periodic spiritual accompaniment and care
Description: Systematic and periodic spiritual accompaniment and care
Study: NCT06183541

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
Study: NCT05732922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.
Description: A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
Study: NCT06324123

Intervention type: OTHER
Intervention: Peacetil
Description: Nutraceutical supplement Peacetil for a period of 2 months
Study: NCT06201754

Intervention type: OTHER
Intervention: Measure air quality
Description: Measure air quality, including PM2.5、PM10
Study: NCT05865106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy
Description: Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional speech therapy
Description: Participants will receive treatment maintaining the same frequency as the intervention group.
Study: NCT05677971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection
Description: Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Study: NCT05596045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC10
Description: Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive placebo
Study: NCT04897776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Thalamic Stimulation
Description: Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hippocampal Stimulation
Description: The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hippocampal Stimulation
Description: The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
Study: NCT05962242

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiation to Head and Neck

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiation to Head and Neck

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiation to Head and Neck

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiation to Head and Neck
Study: NCT04916535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic flow
Description: exams to estimate the risk of adverse events in patients with MAD
Study: NCT05754450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-803
Description: L-fucose crystalline powder
Study: NCT05666076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve block
Description: The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block
Description: The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study: NCT04913012

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic aerobic training
Description: Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systematic aerobic training
Description: Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic resistance training
Description: Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systematic resistance training
Description: Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerobic training booster sessions
Description: Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Resistance training booster sessions
Description: Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).